ENO2 and colorectal carcinoma: Although we clarified that circRHOBTB3 could inhibit CRC progression by repressing EMT and interacting with the metabolic enzymes ENO1 and ENO2, it is still a great challenge for us to target tumor-suppressive circRNAs for CRC therapy.